OR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury

Southeast University, China

Status: Enrolling

Conditions: Myocardial Ischemia-Reperfusion Injury

Treatments: Diagnostic Test: Blood Biomarker Profiling and Prognostic Follow-up

Study type: Observational

Funder types: Other

Identifiers

NCT07100457

2020ZDSYLL051-P01

Details and patient eligibility

About

This study examines how the interaction between octanal (an OR6A2 receptor activator) and OR6A2 expression influences inflammation and clinical outcomes in Myocardial Ischemia-Reperfusion Injury patients. We analyze two key relationships: 1) The octanal-OR6A2 pathway's association with systemic oxidative stress/inflammatory biomarkers, and 2) How OR6A2 expression patterns on monocyte subtypes and plasma octanal levels correlate with major cardiovascular events. Patients undergoing this post-revascularization injury provided blood samples for OR6A2/octanal/inflammation measurements. IR Injury patients underwent 44-month clinical follow-up. Results may identify biological markers for personalized risk assessment after revascularization therapies. Ethics approval: Zhongda Hospital #2020ZDSYLL051-P01.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Acute myocardial infarction (AMI) patients with angiographically-confirmed coronary artery disease undergoing primary percutaneous coronary intervention (PCI), and subsequently diagnosed with protocol-defined myocardial ischemia-reperfusion injury during the post-PCI period.
2. Age 18-90 years inclusive.

Exclusion criteria

1. Active systemic infections.
2. Advanced heart failure (NYHA class III-IV).
3. Acute cerebrovascular conditions.
4. Active myocarditis.
5. cardiomyopathy.
6. Refractory ventricular tachycardia/fibrillation.
7. Diagnosis/concurrent treatment for malignancy within 5 years (except non-melanoma skin cancer/carcinoma in situ).
8. Severe renal insufficiency (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73m2 or dialysis dependence).
9. Child-Pugh class C hepatic dysfunction.

Trial design

200 participants in 1 patient group

Patients With Myocardial Ischemia-Reperfusion Injury

Treatment:

Diagnostic Test: Blood Biomarker Profiling and Prognostic Follow-up